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ABSTRACT 
RATIONALE: A current challenge for analytical chemists is the development of 
measurement systems and approaches required to understand dynamic processes such as 
tablet dissolution.  The design and development of oral tablets could be improved by the 
availability of detailed information about the rates of release of the individual tablet 
components.  Small footprint mass spectrometry (MS) systems are gaining use for on-line 
reaction monitoring because of their ability to rapidly determine multiple reactant, 
intermediate, and product species.  We have therefore assessed the utility of such MS systems 
to the study of dissolution processes. 
 
METHODS: Aqueous dissolution media containing phosphate and other non volatile buffer 
salts were pumped from a standard USPII dissolution vessel through an active splitter and 
back.  The splitter sampled the dissolution stream and diluted it into a make-up flow which 
was pumped to a small single quadrupole mass spectrometer. Single ion monitoring was used 
to quantify the ions of interest. Three different bio-relevant dissolution media were studied to 
gauge the impact of the sample matrix. 
 
RESULTS: Individual dissolution profiles were obtained from a tablet containing three drugs 
and lactose as the soluble filler. This was successfully demonstrated with three different bio-
relevant media designed to reflect the pH of the different sections of the human gastro-
intestinal tract. Component concentrations as low as 0.06 µg/mL (representing 1% 
dissolution) were detected. The MS dissolution profiles correlated with the visual observation 
of tablet dissolution.  MS gave linear responses with concentration for the individual 
components, although analysis of the tablet solution indicated that ion suppression is an area 
for further investigation 
 
CONCLUSIONS: An on-line MS system was used to determine the individual dissolution 
profiles of three drugs and lactose as they are released from the same tablet.  The level of each 
of these components in solution was determined every 10 seconds, and each had a similar 
release profile.  The dissolution profiles were determined using inorganic buffer solutions at 
three different bio-relevant pHs. 
 
 
 
 
INTRODUCTION 
Pharmaceuticals are typically administered as solid oral tablets but for the drug to be available 
for absorption in the Gastro Intestinal Tract (GIT) it must be in solution.  Therefore, the 
process whereby the tablet disintegrates and the components dissolve and disperse (tablet 
dissolution) is of great importance.  Because of this, standardized dissolution testing 
equipment was introduced in the 1970s and 1980s as a Quality Control (QC) measure.
[1, 2]
 In 
recent years the dissolution test has also been used as a tool to improve understanding of 
dissolution mechanisms, and so aid in the design and development of new formulations.  The 
expectation of regulatory authorities is also that the conditions used in the registered 
dissolution test will be related to those which exist in the GIT.  This has led to increasing 
emphasis on the use of dissolution media with pHs and other characteristics which are 
relevant to those of the GIT.  For example, HCl/NaCl buffers at pH 1.2 simulate the fasted 
state of the stomach, acetate buffers at pH 4.5 the fed state of the stomach, and phosphate 
buffers at neutral pHs the conditions in the small intestine. 
[3] 
Recent reviews have also 
emphasised the need for better in vitro tools that are predictive of in vivo behavior. 
[4]
 There is 
therefore a need for improved analytical methods to improve our understanding of tablet 
dissolution processes.  
Conventional analytical approaches to dissolution rely on using sampling and single 
wavelength UV measurement to determine the extent of drug release at a small number of 
time-points.  This approach is adequate for QC purposes but is not very helpful in establishing 
the underlying mechanisms which control drug release.  More helpful are high performance 
liquid chromatography (HPLC) methods and on-line fibre-optic UV spectroscopy. 
[5-7]
 These 
approaches mean that the release of multiple UV absorbing components can be followed, and 
there are sufficient time-points to think of dissolution in terms of a process with associated 
kinetics and rates.  
Pharmaceutical formulations contain many components but typically only the drug has 
a UV chromophore.  This means if we are to understand the role of these components in tablet 
dissolution, we need to look beyond UV measurement. 
Coombes et al, investigated the potential of nuclear magnetic resonance (NMR) spectroscopy 
to monitor the dissolution process.
[8]
 NMR allowed for greater analyte selectivity and had the 
ability to detect non-UV-absorbing species such as sugars. This method, however, relies on 
large NMR instruments, which are fixed to one site and cannot easily be moved around to be 
near the dissolution instrumentation.  
To the best of our knowledge the application of mass spectrometry (MS) to monitor 
dissolution has not been previously reported, and it this that we report here. On-line MS is 
potentially a sensitive and selective method to monitor dissolution: allowing constituents to be 
monitored at low concentrations, based solely on mass-to-charge ratio. Like the NMR method, 
it overcomes problems surrounding the need for UV chromophores, allowing numerous 
individual constituents (including excipients) to be monitored simultaneously, without the 
limitation of spectral overlap, as experienced by UV.
[7] 
 
On-line monitoring of chemical reactions by MS has previously been described; MS 
can provide considerable detail about starting materials, intermediates and products, as well as 
identifying route-specific impurities along the way.
[9-14]
 Such an approach has clear 
application in the monitoring of a dynamic process such as dissolution, as a number of tablet 
components are monitored in real time in a selective and accurate manner. 
Recent developments in small footprint atmospheric pressure ionisation transportable 
mass spectrometers allow instruments to be easily positioned alongside the reaction system. 
The low cost of these systems relative to NMR makes on-line MS a much more cost-effective, 
but still selective, option for dissolution monitoring. The instrument can easily be taken to the 
sample and effectively interfaced with numerous dissolution set-ups.
[15-17] 
 
For MS detection to be a suitable technique for monitoring of dissolution, certain criteria must 
be met: 
1) The response must be linear within the required dynamic range and in the 
presence of non-volatile dissolution buffers; 
2) There must be suitable selectivity between analytes and ions formed from the 
dissolution media or other components of the tablet; 
3) The sensitivity for each component must be such that 10 % dissolution can be 
detected, to aid in understanding the underlying mechanisms of drug release; 
4) Insoluble material present in the dissolution bath must not interfere with the 
analysis; and 
5) The frequency of measurement must be sufficient to define the profile of the 
species present. 
 
To achieve these criteria, the sample taken must be representative of the dissolution 
sample while also being compatible with the mass spectrometer. However, dissolution 
experiments are commonly performed in non-volatile bio-relevant media such as fasted state 
simulated intestinal fluid (FaSSIF) which is a phosphate-containing buffer. These media are 
not commonly interfaced with MS due to the detrimental effects of non-volatile buffers on 
ionisation. Relevant steps therefore should be imposed to allow successful monitoring in this 
medium to ensure compatiblity with the MS detection method.
[18-19] 
 
Other commonly used dissolution media include simulated gastric fluid (SGF) and 
Fed state simulated intestinal fluid (FESSIF, an acetate buffer). These three buffers mimic 
different states and parts of the gastro-intestinal tract, by simulating different pH 
environments commonly experienced by solid dosage forms.
[3] 
 
In this paper we describe real-time monitoring of the dissolution of a solid dosage 
form using a small footprint mass spectrometer. Dissolution of the tablet using a variety of 
common buffers was successfully carried out and the potential for using MS to monitor 
dissolution is demonstrated. 
 
 
EXPERIMENTAL SECTION 
MATERIALS:  
A widely available over-the-counter cold and flu tablet was investigated, containing the three 
Active Pharmaceutical Ingredients (APIs) (i) acetaminophen (250 mg), (ii) guaifenesin (100 
mg), and (iii) phenylephrine hydrochloride (5 mg) as well as (iv) α -lactose monohydrate (190 
mg), as an excipient. The immediate release formulation aims to reduce fever 
(acetaminophen) and act as an expectorant (guaifenesin) and a decongestant (phenylephrine 
hydrochloride) to relieve patientsÕ symptoms.  
Acetaminophen, guaifenesin, phenylephrine hydrochloride and lactose α-monohydrate 
were obtained from Sigma-Aldrich Company Ltd (Gillingham, UK) and used without further 
purification.  
The sample make-up flows used are as described in Table 1. Formic acid and 
ammonium acetate used were obtained from Fisher Scientific (Loughborough, UK), analytical 
grade acetonitrile was obtained from Sigma-Aldrich and de-ionised water from a MilliQ unit 
(Millipore, Watford, UK). 
The compositions of the dissolution media are shown in Table 2. The dissolution 
standards were dissolved in either 900 mL of water or the relevant dissolution media to that 
experimental series. 
 
 
Table 1 Composition of make-up flows for dissolution media used 
Dissolution medium Make-up flow 
FaSSIF 0.1 % formic acid in (50:50 MeCN/H2O) 
SGF 0.1 % formic acid in (50:50 MeCN/H2O) 
Acetate buffer 0.1 % ammonium acetate in (50:50 MeCN/H2O) 
 
Table 2 Dissolution media (all reagents obtained from Sigma-Aldrich) 
Medium pH Reagents 
Blank FaSSIF 6.8 Sodium dihydrogen phosphate 0.2 M  
Sodium hydroxide 0.2 M 
Pure water 
SGF 1.2 Sodium chloride 0.2 M 
HCL 0.2 M  
Pure water 
Acetate buffer 4.5 Sodium acetate trihydrate 2.99 g 
Glacial acetic acid 1.6 mL 
Pure water 1 L 
 
METHODS:  
COMPONENTS & TABLET DISSOLVED IN WATER / FaSSIF: 
Initial investigations were performed with a sample introduced using a syringe pump (11 plus, 
Harvard apparatus, Cambridge, UK), operating at a flow rate of 5 µL/min. The sample entered 
the mass rate attenuator (MRA; Rheodyne, Rohnert Park, CA, USA), an active splitter,  where 
the flow was sampled and diluted (1000:1 split ratio) into a make-up flow from the HPLC 
pump (515, Waters, Manchester, UK) operating at a flow rate of 1 mL/min, and was passed 
into the mass spectrometer.  
Individual components were dissolved in water (concentration representative of 
analyte content in tablet / dissolution volume of 900 mL), and then diluted to create a series 
representing 0-100 % dissolution. The same set of dilutions were also performed in FaSSIF. 
Samples were analysed by positive ion electrospray ionisation (ESI+)-MS using a α-QDa 
single quadrupole mass spectrometer  (Waters), capable of detecting ions  up to m/z 1250. The 
α-QDa is a small footprint mass spectrometer (dimensions: 35.3 x 20 x 75cm) that is 
transportable because of its low weight (approx 30kg). The MS conditions were kept constant 
with a source temperature of 100 ¡C, a probe temperature of 300 ¡C, a capillary voltage of 1.5 
kV and cone voltage 25 V.  
 
ON-LINE DISSOLUTION MONITORING: 
 
Figure 1 Apparatus used to measure dissolution using online mass spectrometry 
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Figure 1 shows the configuration used when connecting the mass spectrometer to the 
dissolution bath. An Agilent 1100 Quaternary pump (Agilent Technologies, Stockport, UK) 
was used to pump the medium from the dissolution bath (through a standard Inlet filter in the 
dissolution bath). A KrudKatcher 0.5µm on-line filter (Phenomenex, Macclesfield, UK) was 
placed in-line just prior to the MRA to prevent any solid material blocking the MRA. The 
MRA sampled and diluted the flow from the bath into the make-up flow which then passed to 
the mass spectrometer as described above. The remaining effluent is pumped back into the 
dissolution bath. A bridge of PEEK tubing was used for the make-up flow entering the MRA 
to reduce pressure fluctuations which produced a more even signal response. 
 Dissolution experiments were performed using a homemade USP II like system,
[8] 
900 
mL of dissolution medium, a paddle speed of 53 rpm, a water bath temperature of 37¡C, a 
flow rate of 1 mL/min from the dissolution bath and an MRA split ratio of 100:1 (decrease in 
ratio from initial investigations so that a greater volume of dissolution effluent was sampled, 
thus providing an improved MS response). Filters were used at sample inlet as well as in-line, 
both prior to the MRA and prior to the MS capillary.  
For each dissolution medium used, primary ESI+ investigations were performed with 
the α-QDa mass spectrometer in scan mode to determine the most abundant ion present for 
each component and to optimise the composition of the make-up flow. This ensured that the 
maximum ionisation of components was achieved (data not shown) through appropriate 
choice of buffer. The four individual components were dissolved in each of the respective 
media at a concentration representative of 100 % dissolution. These solutions were then 
infused into the dissolution setup and the most abundant ion selected in scan mode was then 
employed in single ion recording (SIR) mode to monitor each component. During dissolution 
experiments a dwell time of 0.245 s was used for each ion, with all four ions being monitored 
within one experiment. The SIR data for the 100% dissolution standards could then be used 
for comparison with the tablet dissolution data. 
Prior to a dissolution experiment, the system was flushed first with water and then 
with the respective dissolution medium. The dissolution vessel was sampled to equilibrate the 
system and ensure background measurement. Testing was initiated upon addition of the tablet 
to the vessel and starting of MS on-line monitoring. Following a dissolution experiment, the 
system was flushed with the relevant medium until only background levels of the ions of 
interest were observed. Water and/or methanol flushes were performed where required to 
return signals to normal. 
Three commonly used dissolution media were investigated: FaSSIF (7 tablets), SGF (6 
tablets) and acetate buffer (2 tablets). Dissolution profiles were monitored for at least 15 
minutes with measurements of the intensity of the individual ions taken every 10 s.  
 
 
RESULTS & DISCUSSION 
COMPONENTS & TABLET DISSOLVED IN WATER / FaSSIF:  
Initial investigations were performed using a syringe pump to introduce the tablet components 
dissolved in water. This provided insight into the sensitivity of response and the ionisation of 
each component. As well as showing how reproducible the results were, this approach also 
demonstrated the stability of the MS response over time, as samples were injected over 5-min 
periods. The four ions of interest for the tablet components were selectively monitored (Table 
3). 
 
 
 
 
Table 3 Mass-to-charge ratio (m/z) of the most abundant ions for each component of interest 
in water 
Component Ion m/z 
Acetaminophen [M+H]
+
 152 
Guaifenesin [M+Na]+ 221 
Phenylephrine hydrochloride [M+H-H2O]
+
 150 
Lactose  [M+Na]
+
 365 
 
The same procedure was then performed by dissolving the APIs and the lactose standards in 
blank FaSSiF buffer, a commonly used dissolution medium, representative of fluid from the 
intestine in its fasted state. This allowed the effect of FaSSIF on ionisation to be understood 
and also allowed a more direct comparison with conditions to be used in the dissolution test 
itself. Figure 2 shows linearity of response of guaifenesin when dissolved in water, with an R
2
 
of 0.9982. Ion abundance in excess of 9 E+06 was observed at a concentration equivalent to 
100 % dissolution. This linearity was retained (R
2 
= 0.9938) when guaifenesin was analysed 
in FaSSIF, with a reduction in ion abundance at each concentration. The reduction in response 
is probably a matrix effect causing a change in the ionisation efficiency of guaifenesin, 
compared to the idealised water system. 
Each data point plotted in Figure 2 is also the result of at least three analyses, 
demonstrating the results are reproducible in both systems, with the linear trend remaining 
throughout. This suggests a robust method, stable MS response and reproducible ionisation, 
although sample suppression is observed.  
 
 
Figure 2 Guaifenesin dissolved in water and in FaSSIF, diluted to represent 0 Ð 100% 
dissolution (data of n≥3 shown). 
 
 
 
ON-LINE DISSOLUTION MONITORING IN FASSIF:  
The four ions of interest were selectively monitored (Table 4), one for each of the three APIs 
and one for lactose, for a time scale of 30 min, enough to visualise tablet disintegration and a 
full dissolution profile.  
 
Table 4 Mass-to-charge ratios (m/z) of the most abundant ions for each component of interest 
in all three dissolution media 
Component Ion m/z 
Acetaminophen [M+H]
+
 152 
Guaifenesin [M+Na]
+
 221 
Phenylephrine hydrochloride [M+H-H2O]
+
 150 
Lactose (in FaSSIF) [M+H]
+
 343 
Lactose (in SGF & acetate buffer) [M+Na]
+
 365 
Note that we monitored the lactose [M+H]
+
 ion in FaSSIF and the [M+Na]
+
ion in SGF, 
acetate buffer and water. 
 
Figure 3 shows the dissolution profile of a tablet in FaSSIF. It is clear that each of the four 
components of interest is released from the tablet at a similar rate. Acetaminophen, 
phenylephrine hydrochloride and lactose were released fully from the tablet within a 15-20-
min period, while guaifenesin took longer. This is consistent with the time taken for the tablet 
to fully dissolve, approx. 12 min (in each of the repeats), as shown in Figure 4. 
Whilst the signal for guaifenesin did not appear to plateau in the 30-min time period 
(shown in Figure 3), this did hold true when dissolution was monitored over a 60-min period. 
This phenomenon, however, was also observed during direct infusion of the compound alone 
(dissolved in FaSSIF) as no plateau was obtained after a 1-h infusion. This upward drift of the 
signal was, however, only observed using FaSSIF. As the tablet had reached full 
disintegration (Figure 4) after ~12-min and full dissolution after ~30-min, it is likely that 
guaifenesin dissolution had reached near completion after the 30-min period seen in Figure 3 
(or at least shortly afterwards). This increasing guaifenesin signal has not as yet been 
explained. 
Figure 2 shows the suppression effect of FaSSIF on the guaifenesin signal; however, 
monitoring the dissolution of phenylephrine and guaifenesin produced a response greater than 
would be expected for 100 % dissolution compared with infusion of the compounds alone, 
whereas lactose achieved a response equivalent to only 50 % dissolution. It can be inferred 
that with the FaSSIF medium  the guaifenesin and phenylephrine ions are experiencing an 
enhancement effect from another tablet component and, conversely, the lactose ion is 
experiencing a suppression effect. 
[20]
 
The dissolution profiles are similar to those obtained by Coombes et al. who 
investigated the same dosage form by H
1
-NMR analysis.
[8]
 They also observed that the 
dissolution process began quickly and reached 100 % dissolution after about 15 min for all 
four components with similar release rates for all components. This comparison also suggests 
that the guaifenesin phenomenon is an artifact of our system, as well as suggesting we are 
experiencing possible suppression of the lactose [M+H]
+
 ion at m/z 343 in FaSSIF. The 
suppression and enhancement effects observed require further significant fundamental 
investigation of the observations to fully validate the methodology. 
From Figure 4, it is apparent that the most significant changes in tablet disintegration 
happen within the first 10 min (Figure 4(A)). Less noticeable changes then occur over the 
next 5 min (the tablet becomes fully dissolved after approximately 12 min), and the 
dissolution vessel becomes slightly cloudier over the remaining 15 min (Figure 4(B)) as 
particles in suspension dissolve further. 
 
Figure 3 Dissolution profiles of each component in FaSSIF buffer  (typical data of n=7 
shown, background signal subtracted). 
 
 
 
Figure 4 Photographs of tablet disintegration in FaSSIF: (A) early stages showing most 
significant changes in tablet morphology and (B) later stages of dissolution process. 
A 
B 
DISSOLUTION MONITORING IN SGF:  
Figure 5 shows the dissolution profile for a tablet in SGF. It can be seen that the tablet 
dissolved much more quickly in the SGF than in both other dissolution media investigated, 
with the tablet fully dissolved in approx. 8 min (true for four repeats). This was in agreement 
with the visual data. This is again consistent with the plateauing of the dissolution profiles 
shown in Figure 5 after approx. 12 - 13 min in the case of acetaminophen, guaifenesin and 
lactose, with phenyephrine hydrochloride following shortly afterwards.  
 
 
Figure 5 Dissolution profiles of all tablet components in SGF buffer (typical data of n=5 
shown, background signal subtracted). 
 
Interestingly, one tablet took much longer to disintegrate than expected, approximately 15 
min. This is represented in the MS data (Figure 6) and visualised in the photographs taken 
(not shown). As can be seen in Figure 6, none of the four components reached even 10 % 
dissolution (compared with the standard in SGF) after a 15-min time period. After this time, 
photographs suggested that the dosage form was fully disintegrated, however. On previous 
occasions the dosage form released all four components with dissolution in excess of 90 % 
(Figure 5) after this time. Subsequent tablet analysis produced profiles like those observed in 
Figure 5, indicating the system was functioning correctly but issues with sampling cannot be 
ruled out. Further work is required to understand these differences. 
 
Figure 6 Dissolution profiles of the four components when tablet disintegrated unusually 
slowly in SGF (background signal subtracted). 
 
DISSOLUTION MONITORING IN ACETATE BUFFER:  
Figure 7 shows the dissolution profile for a tablet in acetate buffer. It can be seen that each of 
the four tablet components takes around 20-25 min to become completely released from the 
tablet. This was consistent with the tablet dissolving slowest in this medium, taking around 15 
min to become fully dissolved in the two repeats. Interestingly, the components are released at 
slightly different rates here, with the acetaminophen and lactose being released at similar rates, 
and likewise the guaifenesin and phenylephrine. 
 
Figure 7 Dissolution profile of each respective component (typical data of n=2 shown, 
background signal subtracted). 
 
When comparing the three dissolution media, the four tablet components are released from 
the dosage form at similar rates (with only slight differences in rate observed in the acetate 
buffer). This is consistent with what was found by Coombes et al. using H
1
-NMR
[8]
 to 
investigate the same dosage form, and would suggest that the same underlying mechanism(s) 
control the rate of release of all four tablet components. This information enables a more 
complete understanding of the fundamental tablet dissolution process. Coombes et al. 
suggested that the tablet may disintegrate to produce small particles and that the soluble 
components are then released rapidly from those particles. Taking this suggestion into account, 
perhaps we can begin to explain the changes in dissolution profile seen across the different 
media. Given that all three APIs monitored as well as lactose are highly water-soluble and are 
neutral, changes in pH would be unlikely to alter the dissolution of these components. 
However, if the mechanism Coombes et al. postulate is correct, perhaps it is the disintegration 
of the tablet that is being influenced by the change in buffer. In certain instances 
disintegration can be a critical parameter of drug release, and the change in pH here may, for 
example, be altering this step, changing the rate of particle formation and consequently the 
rate of component release. 
[20]
 Hence we see differences both in the time taken for the tablet to 
dissolve visually and in the MS data. Thus, the criteria initially stated for successful 
interfacing of mass spectrometry to dissolution have been achieved: 
 
1) The linearity of response has been demonstrated in the presence of dissolution 
buffer (Figure 2) although some suppression in signal is observed. Furthermore, 
analysis in the presence of non-volatile buffers using this method did not 
significantly reduce the performance of the instrument; however to maintain this 
performance, the source was regularly cleaned to prevent any build up of non-
volatile buffers. 
2) No interference has been observed between components. 
3) Detection of 10 % dissolution was achieved for all four analytes. 
4) The use of in-line filters meant that no effect was observed from insoluble 
material from the tablet and no issues with blocking were observed from insoluble 
tablet components or non-volatile buffers.  
5) The frequency of sampling has been shown to be sufficient to follow the profile of 
the species as they are released and is generally greater than would be traditionally 
be obtained by off-line LC/UV. 
 
 
CONCLUSIONS 
We have successfully demonstrated, for the first time to the best of our knowledge, that on-
line mass spectrometry can be used to monitor the dissolution of pharmaceutical tablets 
containing non-chromophore-containing components. This technique enables multiple APIs 
and excipients to be monitored simultaneously. We have observed inconsistencies in the 
results and the causes of these need to be more fully understood, although we believe them to 
be caused by suppression and enhancement effects. Further work is required to allow accurate 
quantitation of drug substance dissolution. 
Non-volatile buffers such as FaSSIF have not proved to be a problem provided that a 
suitable make-up flow and sample dilution are used. We have also shown that dissolution 
media such as SGF and acetate buffer can be interfaced with this detection method, offering a 
versatile dissolution monitoring facility. 
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